Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• ENESTPathIndependent statistical analysis of A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.: primary endpoint results, effect estimate…Phase 3Results postedn = 620NCT01743989
• ENHANCEIndependent statistical analysis of Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 539NCT04313881
• Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 66NCT01796470
• EPICIndependent statistical analysis of Mechanisms of EPO-induced Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03810911).Phase 2Results postedn = 27NCT03810911
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 31NCT00400686
• Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 7NCT00258440
• ESCAPEDIndependent statistical analysis of Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 483NCT02411396
• Etoposide in Patients With COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Etoposide in Patients With COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356690).Phase 2Results postedn = 8NCT04356690
• Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: Complete Statistical AnalysisIndependent statistical analysis of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 101NCT00357500
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 72NCT00472290
• Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 1,754NCT04033640
• Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 51NCT06063603
• Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin’s Lymphoma (NHL) Weighing Less Than 70 Kilograms: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms: primary endpoint results, effect estimate with…Phase 4Results postedn = 61NCT01164475
• Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 14NCT06047210
• EVIDENCEIndependent statistical analysis of Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 67NCT02614898
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: primary endpoint results, effect estimate with…Phase 2Results postedn = 2NCT03717480
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 8NCT02530515
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload: Complete Statistical AnalysisIndependent statistical analysis of Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,683NCT00235391
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.: Complete Statistical AnalysisIndependent statistical analysis of Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.: primary endpoint results,…Phase 3Results postedn = 161NCT02292446
• Extended Dosing With Eltrombopag for Severe Aplastic Anemia: Complete Statistical AnalysisIndependent statistical analysis of Extended Dosing With Eltrombopag for Severe Aplastic Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01891994).Phase 2Results postedn = 40NCT01891994
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: Complete Statistical AnalysisIndependent statistical analysis of Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02720536).Phase 3Results postedn = 53NCT02720536
• Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 5NCT02363439
• EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 6NCT01186328
• FAIR-HFAn independent statistical analysis of the randomized phase 3 FAIR-HF trial evaluating ferric carboxymaltose versus normal saline in patients with chronic heart failure and iron deficiency.Phase 3n = 456NCT00520780
• Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients: Complete Statistical AnalysisIndependent statistical analysis of Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 703NCT01929408
• Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers: Complete Statistical AnalysisIndependent statistical analysis of Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers: primary endpoint results, effect estimate with…Phase NAResults postedn = 10NCT03538587
• Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 10NCT04506086
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: Complete Statistical AnalysisIndependent statistical analysis of First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: primary endpoint results, effect estimate with confidence interval,…Phase 1Results postedn = 10NCT04075721
• First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Complete Statistical AnalysisIndependent statistical analysis of First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High…Phase 1/2Results postedn = 101NCT05086315
• FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): Complete Statistical AnalysisIndependent statistical analysis of FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 169NCT02448381
• FLUBUTBIIndependent statistical analysis of Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366612).Phase 3Results postedn = 53NCT01366612
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 64NCT00536341
• FOCUSComplete statistical analysis of the FOCUS randomized phase 3 trial comparing liberal and restrictive blood transfusion strategies in surgical patients with cardiovascular disease, including endpoint definitions, reported odds ratios and risk differences,…Phase 3Results postedn = 2,016NCT00071032
• FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 315NCT01302392
• Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 26NCT01898078
• Fresh Versus Old Red Blood Cells for Transfusion: Complete Statistical AnalysisIndependent statistical analysis of Fresh Versus Old Red Blood Cells for Transfusion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01319552).Phase NAResults postedn = 14NCT01319552
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 10NCT04294641
• FRONTIERIndependent statistical analysis of Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 289NCT05085275
• Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): Complete Statistical AnalysisIndependent statistical analysis of Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 99NCT03149055
• GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): Complete Statistical AnalysisIndependent statistical analysis of GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 47NCT05632354
• Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 14NCT00369629
• Haplo/CordIndependent statistical analysis of Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1NCT01050946
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: Complete Statistical AnalysisIndependent statistical analysis of Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01050764).Phase 1/2Results postedn = 10NCT01050764
• HD10Independent statistical analysis of HD10, a 150-patient clinical trial evaluating dual-point PET acquisition in early stage Hodgkin lymphoma patients with bulky lesions, with event-free survival assessed at 1 year.n = 150NCT01399931
• Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia: Complete Statistical AnalysisIndependent statistical analysis of Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 110NCT02625844
• HEART-FIDIndependent statistical analysis of Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 3,065NCT03037931
• Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine: Complete Statistical AnalysisIndependent statistical analysis of Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine: primary endpoint results, effect estimate…Phase NAResults postedn = 21NCT00595127
• Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure: Complete Statistical AnalysisIndependent statistical analysis of Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 55NCT00318812
• Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01405742).Phase 3Results postedn = 4NCT01405742
• Hestia2Independent statistical analysis of A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease: primary endpoint results, effect estimate with…Phase 2Results postedn = 87NCT02482298

← All therapeutic areas